Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule inhibitor with the IUPAC name (2S)-2-{[3-(3‑aminophenyl)imidazo[1,2‑b]pyridazin‑6‑yl]amino}‑3‑methylbutan‑1‑ol. It belongs to the class of aromatic heteropolycyclic compounds and azoles. The compound has been identified as an experimental agent and is known to act as an inhibitor of serine/threonine-protein kinase haspin. Haspin is a nuclear protein kinase involved in chromatin regulation and cell cycle progression. Inhibition of haspin may have potential applications in cancer therapy due to its role in mitosis regulation. The compound’s development status appears limited to preclinical or early-stage research settings; there are no indications it has advanced into clinical trials or received regulatory approval for any indication.[1][2][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol.